Education
About Us
Working with TipRanks
Follow Us
Equillium Inc (EQ)
NASDAQ:EQ
EQ Stock Chart & Stats
$1.15
-$0.05(-6.85%)
At close: 4:00 PM EST
$1.15
-$0.05(-6.85%)
Day’s Range― - ―
52-Week Range$0.27 - $2.35
Previous CloseN/A
Volume484.47K
Average Volume (3M)883.61K
Market Cap
$70.03M
Enterprise Value$22.73K
Total Cash (Recent Filing)$33.12M
Total Debt (Recent Filing)$745.00K
Price to Earnings (P/E)―
Beta-0.17
Next Earnings
Mar 26, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding60,893,284
10 Day Avg. Volume862,141
30 Day Avg. Volume883,611
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.39
Price to Sales (P/S)0.64
P/FCF Ratio-1.38
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Data SupportThe pre-clinical data generated is encouraging and provides supporting evidence for EQ504 as a promising treatment for UC.
Financing And InvestmentEQ's recent $30M financing marks a new chapter as Co pivots to a new lead pipeline asset, focused initially on the large commercial opportunity in Ulcerative Colitis (UC).
Market PotentialWith increasing attention on Abivax's Obefazimod and its recent positive results in UC, there is potential for an upward move in EQ stock as it shares a similar impact on IL-10 and IL-22 modulation.
Bears Say
Equillium News
EQ FAQ
What was Equillium Inc’s price range in the past 12 months?
Equillium Inc lowest stock price was $0.27 and its highest was $2.35 in the past 12 months.
What is Equillium Inc’s market cap?
Equillium Inc’s market cap is $70.03M.
When is Equillium Inc’s upcoming earnings report date?
Equillium Inc’s upcoming earnings report date is Mar 26, 2026 which is in 95 days.
How were Equillium Inc’s earnings last quarter?
Equillium Inc released its earnings results on Nov 13, 2025. The company reported -$0.06 earnings per share for the quarter, beating the consensus estimate of -$0.07 by $0.01.
Is Equillium Inc overvalued?
According to Wall Street analysts Equillium Inc’s price is currently Overvalued.
Does Equillium Inc pay dividends?
Equillium Inc does not currently pay dividends.
What is Equillium Inc’s EPS estimate?
Equillium Inc’s EPS estimate is -0.05.
How many shares outstanding does Equillium Inc have?
Equillium Inc has 60,893,284 shares outstanding.
What happened to Equillium Inc’s price movement after its last earnings report?
Equillium Inc reported an EPS of -$0.06 in its last earnings report, beating expectations of -$0.07. Following the earnings report the stock price went up 23.81%.
Which hedge fund is a major shareholder of Equillium Inc?
Currently, no hedge funds are holding shares in EQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Equillium Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
― (―)
― (―)
Hedge Fund Trend
Increased
By 2.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 3.4%
Last 30 Days ▼ 6.3%
Last 30 Days ▼ 6.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
35.18%
12-Months-Change
Fundamentals
Return on Equity
-90.24%
Trailing 12-Months
Asset Growth
-71.07%
Trailing 12-Months
Company Description
Equillium Inc
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
Technical Analysis
NRX Pharmaceuticals
―
Sutro Biopharma
―
MindWalk Holdings
―
Prelude Therapeutics
―
Coeptis Therapeutics Holdings
―
Ownership Overview
29.79% Insiders
2.12% Mutual Funds
39.09% Other Institutional Investors
26.22% Public Companies and
Individual Investors